SCHEMBL2953908

SCHEMBL2953908

COC(=O)c1ccc(OCCN(C)C)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.74
RAB9A P51151 2/20 0.66
ALDH1A1 P00352 2/20 0.61
TDP1 Q9NUW8 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
HRH3 Q9Y5N1 3/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
BCHE P06276 1/20 0.55
ACHE P22303 1/20 0.55
DRD2 P14416 1/20 0.54
DRD3 P35462 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPC1 O15118 1/20 0.53
GAA P10253 1/20 0.52
TSHR P16473 1/20 0.52
ESR1 P03372 1/20 0.52
ESRRB O95718 2/20 0.52
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8137583 0.95 MAPT (0.68) MAPTRAB9AALDH1A1TDP1L3MBTL1
SCHEMBL4966044 0.92 MAPT (0.72) MAPTRAB9AALDH1A1TDP1L3MBTL1
SCHEMBL8134959 0.86 ALDH1A1 (0.62) MAPTRAB9AALDH1A1HRH3BCHE
SCHEMBL1951546 0.86 MAPT (1.00) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL6057420 0.84 ESR1 (0.59) MAPTRAB9AALDH1A1HRH3BCHE
SCHEMBL2469151 0.84 MAPT (0.89) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL4473605 0.84 MAPT (0.70) MAPTRAB9ATDP1L3MBTL1HRH3
SCHEMBL3134314 0.84 MAPT (0.76) MAPTRAB9AALDH1A1TDP1L3MBTL1
SCHEMBL1981044 0.83 PKM (0.62) MAPTRAB9AALDH1A1HRH3BCHE
SCHEMBL13461848 0.83 MAPT (0.79) MAPTRAB9ATDP1L3MBTL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404243-B2 Inhibitors of the Wnt/beta-catenin pathway THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-02 US disclosed
EP-3749640-B1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY UNIV CALIFORNIA (US) 2025-07-16 EP disclosed
EP-4581017-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS Biodol Therapeutics (FR) 2025-07-09 EP disclosed
WO-2024079072-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS BIODOL THERAPEUTICS (FR) 2024-04-18 WO disclosed
EP-4353712-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS Biodol Therapeutics (FR) 2024-04-17 EP disclosed
US-20240059654-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-02-22 US disclosed
US-11708329-B2 Inhibitors of the WNT/beta-catenin pathway THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-07-25 US disclosed
US-20210371384-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
EP-3749640-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY The Regents of the University of California (US) 2020-12-16 EP disclosed
WO-2019152536-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-08-08 WO disclosed
US-20080306068-A1 Suppression cytokines, tumor necrosis factor ELI LILLY AND COMPANY (US) 2008-12-11 US disclosed
EP-1761520-B1 KINASE INHIBITORS LILLY CO ELI (US) 2008-07-09 EP disclosed
EP-1761520-B1 KINASE INHIBITORS LILLY CO ELI (US) 2008-07-09 EP disclosed
EP-1761520-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-03-14 EP disclosed
WO-2006009741-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2006-01-26 WO disclosed
US-6177443-B1 ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 2001-01-23 US disclosed
US-6069149-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS TERUMO KABUSHIKI KAISHA (JP) 2000-05-30 US disclosed
EP-0973778-A1 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-01-26 EP disclosed
EP-0894797-A1 NOVEL AMIDE DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF TERUMO KABUSHIKI KAISHA (JP) 1999-02-03 EP disclosed
WO-1998040385-A1 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1998-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708329-B2 Inhibitors of the WNT/beta-catenin pathway CTNNB1, CTNNBL1, CTNND1 MAPT 3908/4885RAB9A 1911/4885ALDH1A1 2704/4885
US-12404243-B2 Inhibitors of the Wnt/beta-catenin pathway CTNNB1, CTNNBL1, CTNND1 MAPT 3908/4885RAB9A 1911/4885ALDH1A1 2704/4885
US-20210371384-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY CTNNB1, CTNNBL1, CTNND1 MAPT 3908/4885RAB9A 1911/4885ALDH1A1 2704/4885
US-20080306068-A1 Suppression cytokines, tumor necrosis factor TNF, TNFRSF1A, IL2 MAPT 4665/4885RAB9A 3581/4885ALDH1A1 2315/4885
US-20240059654-A1 INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY CTNNB1, CTNNBL1, CTNND1 MAPT 3908/4885RAB9A 1911/4885ALDH1A1 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.